Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Negative News from Ionis Pharmaceuticals Phase 3 Trial for Huntington’s Disease. Good News from the Regeneron Antibody Cocktail for COVID-19

March 23, 2021 0

Negative News from Ionis Pharmaceuticals Ionis Pharmaceuticals (IONS) announced that its partner, Roche (RHHBY),

CureVac Has Very Interesting Future Plans

March 22, 2021 0

CureVac CureVac B.V. (CVAC) is a global biopharmaceutical company specializing in messenger RNA (mRNA) technology. The …

AstraZeneca to Supply Half a Million Additional Doses of the Potential COVID-19 Antibody Treatment AZD7442 to the U.S.

March 17, 2021 0

AstraZeneca to Supply Additional Doses of AZD7442 to the U.S. for COVID-19 AstraZeneca (AZN) has modified …

Immutep Ltd: Evaluating the Safety and Efficacy of Eftilagimod Alpha in Combination with Merck’s KEYTRUDA

March 16, 2021 0

Immutep Ltd and Merck Announce Second Clinical Trial Collaboration Immutep (IMMP) develops novel immunotherapy treatments for …

Gilead Sciences and Merck: Long-Term Oral HIV Combination Treatment

March 15, 2021 0

Gilead Sciences and Merck Announced Agreement for Long-Term HIV Combination Treatment Gilead Sciences (GILD) and Merck …

Anixa Biosciences: Why This Firm Outperformed Today

March 12, 2021 0

Anixa Biosciences Outperformance Anixa Biosciences Inc (ANIX) is the worldwide licensee of a patent technology titled …

Aveo Oncology: The FDA Approved FOTIVDA for Adults with Relapsed or Refractory Advanced RCC

March 11, 2021 0

Aveo Oncology Received FDA Approval for FOTIVDA for Advanced RCC Aveo Oncology (AVEO) drug FOTIVDA is …

Vir Biotechnology and GlaxoSmithKline: Independent Data Monitoring Committee Recommends Stopping Phase 3 COMET-ICE Trial Early

March 11, 2021 0

Vir Biotechnology and GlaxoSmithKline Recommended to Stop Phase 3 COMET-ICE Trial Vir Biotechnology (VIR) and GlaxoSmithKline …

bluebird bio Provides Updated Findings of AML in LentiGlobin for SCD Gene Therapy Program

March 10, 2021 0

Updated Findings from bluebird bio bluebird bio analyses demonstrate lentiviral vector BB305 unlikely to be the …

It’s All About Common Sense: Intellia Therapeutics

March 9, 2021 0

The Nonsensical Downgrading of Development-Stage Firms Like Intellia Therapeutics It makes no sense to downgrade a …

Prohost Letter #444

March 8, 2021 0

Prohost Letter #444 The End of the Year Issue was delayed because our 2020 Prohost Portfolio …

The Reasons Why Ovid Therapeutics’ Stock Outperformed Today

March 3, 2021 0

Ovid Therapeutics & Takeda Announce Agreement for Soticlestat Ovid Pharmaceuticals is eligible to receive up to …

The FDA Approved KemPharm Inc’s AZSTARYS™ for ADHD

March 3, 2021 0

KemPharm Inc KemPharm Inc (KMPH) - a specialty pharmaceutical focused on the discovery and development of …

Aslan Pharmaceuticals: A Small Firm with Early, Promising Results for Atopic Dermatitis

March 1, 2021 0

Aslan Pharmaceuticals Aslan Pharmaceuticals (ASLN) is a clinical-stage immunology company announced positive interim unblinded data from …

The Johnson & Johnson COVID-19 Vaccine: Helping to Increase the Pressure on the Virus

March 1, 2021 0

Johnson & Johnson Receives an EUA from the U.S. FDA We appreciate the U.S. Food and …

The QIAGEN and Inovio Pharmaceuticals Partnership Extension

February 25, 2021 0

QIAGEN and Inovio Pharmaceuticals Partnership QIAGEN (QGEN) and Inovio Pharmaceuticals (

Johnson & Johnson COVID-19 Vaccine Voting Tomorrow with Expected Approval on Saturday

February 25, 2021 0

Johnson & Johnson COVID-19 Vaccine According to a new analysis posted online by the FDA, the …

Compugen: Good News During Bad Market Days

February 23, 2021 0

The market is sinking in a furious mood caused by the failure to figure out the …

Regeneron Pharmaceuticals: Good News During Bad Market Days

February 23, 2021 0

The market is sinking in a furious mood caused by the failure to figure out the …

Cassava Sciences: Good News During Bad Market Days

February 23, 2021 0

The market is sinking in a furious mood caused by the failure to figure out the …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Negative News from Ionis Pharmaceuticals Phase 3 Trial for Huntington’s Disease. Good News from the Regeneron Antibody Cocktail for COVID-19

CureVac Has Very Interesting Future Plans

AstraZeneca to Supply Half a Million Additional Doses of the Potential COVID-19 Antibody Treatment AZD7442 to the U.S.

Immutep Ltd: Evaluating the Safety and Efficacy of Eftilagimod Alpha in Combination with Merck’s KEYTRUDA

Gilead Sciences and Merck: Long-Term Oral HIV Combination Treatment

Anixa Biosciences: Why This Firm Outperformed Today

Aveo Oncology: The FDA Approved FOTIVDA for Adults with Relapsed or Refractory Advanced RCC

Vir Biotechnology and GlaxoSmithKline: Independent Data Monitoring Committee Recommends Stopping Phase 3 COMET-ICE Trial Early

bluebird bio Provides Updated Findings of AML in LentiGlobin for SCD Gene Therapy Program

It’s All About Common Sense: Intellia Therapeutics

Prohost Letter #444

The Reasons Why Ovid Therapeutics’ Stock Outperformed Today

The FDA Approved KemPharm Inc’s AZSTARYS™ for ADHD

Aslan Pharmaceuticals: A Small Firm with Early, Promising Results for Atopic Dermatitis

The Johnson & Johnson COVID-19 Vaccine: Helping to Increase the Pressure on the Virus

The QIAGEN and Inovio Pharmaceuticals Partnership Extension

Johnson & Johnson COVID-19 Vaccine Voting Tomorrow with Expected Approval on Saturday

Compugen: Good News During Bad Market Days

Regeneron Pharmaceuticals: Good News During Bad Market Days

Cassava Sciences: Good News During Bad Market Days